Concurrent Activation of Liver X Receptor and Peroxisome Proliferator-Activated Receptor Alpha Exacerbates Hepatic Steatosis in High Fat Diet-Induced Obese Mice

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Gao, Mingming ^a   Bu, Le ^a   Ma, Yongjie ^a   Liu, Dexi ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CD36 ANTIGEN; FAS ANTIGEN; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 21; GLUCOSE TRANSPORTER 4; GLYCEROL; GLYCOPROTEIN P 15095; LEPTIN; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ACC1 GENE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATGL GENE; CD36 GENE; CHREBP GENE; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVATION; ENZYME ACTIVITY; EX VIVO STUDY; FAS GENE; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FATTY LIVER; GENE; GLUCOSE TOLERANCE; GLUT4 GENE; HSL GENE; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; MALE; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCD1 GENE; SREBP 1C GENE;

ADIPOCYTES; ADIPOSE TISSUE, WHITE; ANIMALS; BLOOD GLUCOSE; CELL SIZE; CHOLESTEROL; DIET, HIGH-FAT; FATTY ACIDS; FATTY LIVER; FENOFIBRATE; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; HYDROCARBONS, FLUORINATED; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; ORPHAN NUCLEAR RECEPTORS; PPAR ALPHA; SULFONAMIDES; TRIGLYCERIDES;

MUS;

EID: 84878791042     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065641     Document Type: Article

References (48)

1. Baranowski M, (2008) Biological role of liver X receptors. J Physiol Pharmacol 59Suppl 7: 31-55.
2. Ferre P, (2004) The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53Suppl 1: S43-50.
3. Yue L, Ye F, Gui C, Luo H, Cai J, et al. (2005) Ligand-binding regulation of LXR/RXR and LXR/PPAR heterodimerizations: SPR technology-based kinetic analysis correlated with molecular dynamics simulation. Protein Sci 14: 812-822.
4. Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, et al. (2003) Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol Endocrinol 17: 1255-1267.
5. Yoshikawa T, Ide T, Shimano H, Yahagi N, Amemiya-Kudo M, et al. (2003) Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Mol Endocrinol 17: 1240-1254.
6. Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, et al. (2003) Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 278: 1131-1136.
7. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, et al. (2003) Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A 100: 5419-5424.
8. Gao M, Liu D, (2013) The liver X receptor agonist T0901317 protects mice from high fat diet-induced obesity and insulin resistance. AAPS J 15: 258-266.
9. Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, et al. (2009) Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res 50: 312-326.
10. Fernandez-Veledo S, Nieto-Vazquez I, Rondinone CM, Lorenzo M, (2006) Liver X receptor agonists ameliorate TNFalpha-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression. Diabetologia 49: 3038-3048.
11. Chisholm JW, Hong J, Mills SA, Lawn RM, (2003) The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res 44: 2039-2048.
12. Rosenson RS, (2008) Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 6: 1319-1330.
13. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, et al. (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103: 1489-1498.
14. Minnich A, Tian N, Byan L, Bilder G, (2001) A potent PPAR alpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 280: E270-279.
15. Jeong S, Yoon M, (2009) Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice. Exp Mol Med 41: 397-405.
16. Yoon M, (2009) The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. Pharmacol Res 60: 151-159.
17. Hara A, Radin NS, (1978) Lipid extraction of tissues with a low-toxicity solvent. Analytic Biochem 90: 420-426.
18. Carmona MC, Louche K, Nibbelink M, Prunet B, Bross A, et al. (2005) Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice. Int J Obes (Lond) 29: 864-871.
19. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, et al. (2009) Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 84: 164-172.
20. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
21. Jaworski K, Ahmadian M, Duncan RE, Sarkadi-Nagy E, Varady KA, (2009) AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat Med 15: 159-168.
22. Li AC, Glass CK, (2004) PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 45: 2161-2173.
23. Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, et al. (2002) Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 277: 34182-34190.
24. Oosterveer MH, Grefhorst A, van Dijk TH, Havinga R, Staels B, et al. (2009) Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. J Biol Chem 284: 34036-34044.
25. Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, et al. (2012) Peroxisome proliferator-activated receptor-alpha agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 27: 341-350.
26. Arsov T, Larter CZ, Nolan CJ, Petrovsky N, Goodnow CC, et al. (2006) Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun 342: 1152-1159.
27. Stenson BM, Ryden M, Venteclef N, Dahlman I, Pettersson AM, et al. (2011) Liver X receptor (LXR) regulates human adipocyte lipolysis. J Biol Chem 286: 370-379.
28. Juvet LK, Andresen SM, Schuster GU, Dalen KT, Tobin KA, et al. (2003) On the role of liver X receptors in lipid accumulation in adipocytes. Mol Endocrinol 17: 172-182.
29. Darimont C, Avanti O, Zbinden I, Leone-Vautravers P, Mansourian R, et al. (2006) Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes. Biochimie 88: 309-318.
30. Sekiya M, Yahagi N, Matsuzaka T, Takeuchi Y, Nakagawa Y, et al. (2007) SREBP-1-independent regulation of lipogenic gene expression in adipocytes. J Lipid Res 48: 1581-1591.
31. Ross SE, Erickson RL, Gerin I, DeRose PM, Bajnok L, et al. (2002) Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism. Mol Cell Biol 22: 5989-5999.
32. Cannon B, Nedergaard J, (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84: 277-359.
33. Korach-Andre M, Archer A, Barros RP, Parini P, Gustafsson JA, (2011) Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity. Proc Natl Acad Sci U S A 108: 403-408.
34. Colin S, Bourguignon E, Boullay AB, Tousaint JJ, Huet S, et al. (2008) Intestine-specific regulation of PPARalpha gene transcription by liver X receptors. Endocrinology 149: 5128-5135.
35. Ducheix S, Podechard N, Lasserre F, Polizzi A, Pommier A, et al. (2013) A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARalpha. Biochimie 95: 556-567.
36. Boergesen M, Pedersen TA, Gross B, van Heeringen SJ, Hagenbeek D, et al. (2012) Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor alpha in mouse liver reveals extensive sharing of binding sites. Mol Cell Biol 32: 852-867.
37. Lenhard JM, Lancaster ME, Paulik MA, Weiel JE, Binz JG, et al. (1999) The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. Diabetologia 42: 545-554.
38. Archer A, Venteclef N, Mode A, Pedrelli M, Gabbi C, et al. (2012) Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice. Mol Endocrinol 26: 1980-1990.
39. Lundasen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, et al. (2007) PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 360: 437-440.
40. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, et al. (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5: 415-425.
41. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, et al. (2012) Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 148: 556-567.
42. Mitro N, Vargas L, Romeo R, Koder A, Saez E, (2007) T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett 581: 1721-1726.
43. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830.
44. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808.
45. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P, (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9: 213-219.
46. Im SS, Osborne TF, (2011) Liver x receptors in atherosclerosis and inflammation. Circ Res 108: 996-1001.
47. Zandbergen F, Plutzky J, (2007) PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 1771: 972-982.
48. Kidani Y, Bensinger SJ, (2012) Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol Rev 249: 72-83.